Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xoma

Executive Summary

Reducing workforce by 85 employees and taking a one-time charge of approximately $10 mil. in its third quarter, as part of a restructuring announced Oct. 29. "Due to the delays we have encountered with E5 and CD5 Plus, we are refocusing and streamlining our organization," CEO Jack Castello explained. Xoma will "emphasize" the development of human bactericidal/permeability increasing (BPI) protein-based products for infections and T-cell targeted products for autoimmune disease, while continuing the clinical development of E5 for gram- negative sepsis and CD5 Plus solely for graft-versus-host-disease.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021722

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel